Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group
Por:
Frentz, D, van de Vijver, D, Abecasis, A, Albert, J, Hamouda, O, Jorgensen, L, Kucherer, C, Struck, D, Schmit, JC, Vercauteren, J, Asjo, B, Balotta, C, Bergin, C, Beshkov, D, Camacho, R, Clotet, B, Griskevicius, A, Grossman, Z, Horban, A, Kolupajeva, T, Korn, K, Kostrikis, L, Linka, KLM, Nielsen, C, Otelea, D, Paraskevis, D, Paredes, R, Poljak, M, Puchhammer-Stockl, E, Sonnerborg, A, Stanekova, D, Stanojevic, M, Vandamme, AM, Boucher, C and Wensing, A
Publicada:
10 abr 2014
Categoría:
Multidisciplinary
Resumen:
Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.
Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression.
Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively).
Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.
Filiaciones:
Frentz, D:
Erasmus MC, Dept Virol, Rotterdam, Netherlands
van de Vijver, D:
Erasmus MC, Dept Virol, Rotterdam, Netherlands
Abecasis, A:
Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, P-1200 Lisbon, Portugal
Albert, J:
Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden
Hamouda, O:
Robert Koch Inst, Berlin, Germany
Jorgensen, L:
Statens Serum Inst, DK-2300 Copenhagen, Denmark
Kucherer, C:
Robert Koch Inst, Berlin, Germany
Struck, D:
CRP Sante, Lab Retrovirol, Luxembourg, Luxembourg
Schmit, JC:
CRP Sante, Lab Retrovirol, Luxembourg, Luxembourg
Ctr Hosp Luxembourg, Luxembourg, Luxembourg
Vercauteren, J:
Katholieke Univ Leuven, Rega Inst, Louvain, Belgium
Asjo, B:
Univ Bergen, Gade Inst, Microbiol & Immunol Sect, Bergen, Norway
Balotta, C:
Univ Milan, Milan, Italy
Bergin, C:
St James Hosp, Dept GU Med & Infect Dis, Dublin 8, Ireland
Beshkov, D:
Natl Ctr Infect & Parasit Dis, Dept Virol, Sofia, Bulgaria
Camacho, R:
Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, P-1200 Lisbon, Portugal
Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Lisbon, Portugal
:
Hosp Badalona Germans Trias & Pujol, Lluita SIDA Fdn, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Badalona, Spain
Griskevicius, A:
Natl Publ Hlth Surveillance Lab, Vilnius, Lithuania
Grossman, Z:
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
Horban, A:
Med Univ Warsaw, Warsaw, Poland
Hosp Infect Dis, Warsaw, Poland
Kolupajeva, T:
Infectol Ctr Latvia, Riga, Latvia
Korn, K:
Univ Erlangen Nurnberg, D-91054 Erlangen, Germany
Kostrikis, L:
Univ Cyprus, Nicosia, Cyprus
Linka, KLM:
Natl Inst Hlth & Welf, Helsinki, Finland
Natl Inst Publ Hlth, Prague, Czech Republic
Nielsen, C:
Robert Koch Inst, Berlin, Germany
Otelea, D:
Prof Dr Matei Bals Inst Infect Dis, Bucharest, Romania
Paraskevis, D:
Univ Athens, Sch Med, GR-11527 Athens, Greece
Paredes, R:
Natl Ctr Infect & Parasit Dis, Dept Virol, Sofia, Bulgaria
Poljak, M:
Univ Ljubljana, Ljubljana, Slovenia
Puchhammer-Stockl, E:
Med Univ Vienna, Vienna, Austria
Sonnerborg, A:
Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden
Karolinska Inst, Div Infect Dis, Stockholm, Sweden
Karolinska Inst, Div Clin Virol, Stockholm, Sweden
Stanekova, D:
Slovak Med Univ, Bratislava, Slovakia
Stanojevic, M:
Univ Belgrade, Sch Med, Belgrade, Serbia
Vandamme, AM:
Katholieke Univ Leuven, Rega Inst, Louvain, Belgium
Boucher, C:
Erasmus MC, Dept Virol, Rotterdam, Netherlands
Wensing, A:
Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands
Green Published, gold
|